yon, France, October 28, 2008 Flamel Technologies (NASDAQ:FLML) expects to
release its financial results for the third quarter on Monday, November 3rd, after the market
close. A conference call to discuss the results has been scheduled for Tuesday, November
4th, at 8:30 AM (EST). A question and answer period is expected to follow the discussion of
results.
To participate in the conference call, investors in the US and Canada are invited to
dial 1-800-374-1498. International callers are invited to call 1-706-634-7261. The
Conference ID number is: 71106766.
The conference call webcast may be accessed at www.flamel.com.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the
development of two unique polymer-based delivery technologies for medical applications.
Micropump® is a controlled release and taste-masking technology for the oral administration
of small molecule drugs; it is the intellectual platform licensed by Glaxo Smith Kline for the
development of Coreg CR™. Flamel's Medusa® technology is designed to deliver controlled-
release formulations of therapeutic proteins and peptides.
Contact:
Charles Marlio, Director of Strategic Planning and Investor Relations
tel: (+) 33 (0)4 7278 - 3434
fax: (+) 33 (0)4 7278 - 3435
Marlio@flamel.com
This document contains a number of matters, particularly as related to financial projections
and the status of various research projects and technology platforms, that constitute forward-
looking statements within the meaning of the Private Securities Litigation Reform Act of
1995.
The presentation reflects the current view of management with respect to future events and is
subject to risks and uncertainties that could cause actual results to differ materially from
those contemplated in such forward-looking statements.
These risks include risks that products in the development stage may not achieve scientific
objectives or milestones or meet stringent regulatory requirements, uncertainties regarding
market acceptance of products in development, the impact of competitive products and
pricing, and the risks associated with Flamel's reliance on outside parties and key strategic
alliances.
These and other risks are described more fully in Flamel's Annual Report on the Securities
and Exchange Commission Form 20-F for the year ended December 31, 2007.
